Sarepta Therapeutics (NASDAQ:SRPT) Given Sell Rating at HC Wainwright

Sarepta Therapeutics (NASDAQ:SRPT)‘s stock had its “sell” rating reaffirmed by analysts at HC Wainwright in a research note issued on Wednesday,Benzinga reports. They currently have a $75.00 target price on the biotechnology company’s stock. HC Wainwright’s target price points to a potential upside of 1.99% from the company’s previous close.

Other analysts have also recently issued research reports about the stock. Piper Sandler decreased their target price on shares of Sarepta Therapeutics from $200.00 to $182.00 and set an “overweight” rating on the stock in a research note on Wednesday, November 27th. Deutsche Bank Aktiengesellschaft assumed coverage on shares of Sarepta Therapeutics in a research note on Tuesday, February 11th. They set a “hold” rating and a $136.00 target price on the stock. Needham & Company LLC reissued a “buy” rating and issued a $202.00 price objective on shares of Sarepta Therapeutics in a research note on Tuesday. Scotiabank assumed coverage on shares of Sarepta Therapeutics in a research note on Friday, March 7th. They issued a “sector perform” rating and a $105.00 price objective on the stock. Finally, Cantor Fitzgerald reissued an “overweight” rating and issued a $163.00 price objective on shares of Sarepta Therapeutics in a research note on Tuesday. One investment analyst has rated the stock with a sell rating, four have given a hold rating, eighteen have given a buy rating and one has given a strong buy rating to the company’s stock. According to data from MarketBeat.com, the stock has an average rating of “Moderate Buy” and an average target price of $168.55.

Sarepta Therapeutics Price Performance

SRPT opened at $73.54 on Wednesday. The company has a quick ratio of 3.03, a current ratio of 3.84 and a debt-to-equity ratio of 0.93. Sarepta Therapeutics has a 12 month low of $73.06 and a 12 month high of $173.25. The company has a fifty day simple moving average of $110.18 and a 200 day simple moving average of $119.13. The stock has a market cap of $7.14 billion, a P/E ratio of 58.83 and a beta of 0.79.

Insiders Place Their Bets

In other Sarepta Therapeutics news, Director Claude Nicaise sold 2,491 shares of the stock in a transaction that occurred on Wednesday, March 12th. The shares were sold at an average price of $99.64, for a total value of $248,203.24. Following the sale, the director now directly owns 27,812 shares in the company, valued at $2,771,187.68. This represents a 8.22 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. Corporate insiders own 7.70% of the company’s stock.

Institutional Trading of Sarepta Therapeutics

Several institutional investors and hedge funds have recently bought and sold shares of SRPT. Sumitomo Mitsui Trust Group Inc. raised its position in shares of Sarepta Therapeutics by 21.4% during the 3rd quarter. Sumitomo Mitsui Trust Group Inc. now owns 1,700 shares of the biotechnology company’s stock valued at $212,000 after buying an additional 300 shares in the last quarter. Oppenheimer Asset Management Inc. raised its position in shares of Sarepta Therapeutics by 3.4% during the 3rd quarter. Oppenheimer Asset Management Inc. now owns 4,457 shares of the biotechnology company’s stock valued at $557,000 after buying an additional 145 shares in the last quarter. Huntington National Bank raised its position in shares of Sarepta Therapeutics by 150.9% during the 3rd quarter. Huntington National Bank now owns 291 shares of the biotechnology company’s stock valued at $36,000 after buying an additional 175 shares in the last quarter. CIBC Asset Management Inc raised its position in shares of Sarepta Therapeutics by 3.3% during the 3rd quarter. CIBC Asset Management Inc now owns 2,712 shares of the biotechnology company’s stock valued at $339,000 after buying an additional 86 shares in the last quarter. Finally, Commerce Bank raised its position in shares of Sarepta Therapeutics by 15.7% during the 3rd quarter. Commerce Bank now owns 2,016 shares of the biotechnology company’s stock valued at $252,000 after buying an additional 274 shares in the last quarter. 86.68% of the stock is currently owned by hedge funds and other institutional investors.

About Sarepta Therapeutics

Sarepta Therapeutics, Inc, a commercial-stage biopharmaceutical company, focuses on the discovery and development of RNA-targeted therapeutics, gene therapies, and other genetic therapeutic modalities for the treatment of rare diseases. It offers EXONDYS 51 injection to treat duchenne muscular dystrophy (duchenne) in patients with confirmed mutation of the dystrophin gene that is amenable to exon 51 skipping; VYONDYS 53 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene that is amenable to exon 53 skipping; AMONDYS 45 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene; and ELEVIDYS, an adeno-associated virus based gene therapy for the treatment of ambulatory pediatric patients aged 4 through 5 years with duchenne with a confirmed mutation in the duchenne gene.